- Home
- VSTE vs CMRX Comparison
VSTE vs CMRX Comparison
Compare VSTE & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTE
- CMRX
- Stock Information
- Founded
- VSTE 2009
- CMRX 2000
- Country
- VSTE Australia
- CMRX United States
- Employees
- VSTE N/A
- CMRX N/A
- Industry
- VSTE
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- VSTE
- CMRX Health Care
- Exchange
- VSTE Nasdaq
- CMRX Nasdaq
- Market Cap
- VSTE 30.0M
- CMRX 77.0M
- IPO Year
- VSTE N/A
- CMRX 2013
- Fundamental
- Price
- VSTE $2.42
- CMRX $0.93
- Analyst Decision
- VSTE
- CMRX Strong Buy
- Analyst Count
- VSTE 0
- CMRX 1
- Target Price
- VSTE N/A
- CMRX $11.00
- AVG Volume (30 Days)
- VSTE 14.1K
- CMRX 119.4K
- Earning Date
- VSTE 01-01-0001
- CMRX 11-08-2024
- Dividend Yield
- VSTE N/A
- CMRX N/A
- EPS Growth
- VSTE N/A
- CMRX N/A
- EPS
- VSTE N/A
- CMRX N/A
- Revenue
- VSTE $342,000.00
- CMRX $144,000.00
- Revenue This Year
- VSTE N/A
- CMRX $3,040.12
- Revenue Next Year
- VSTE N/A
- CMRX N/A
- P/E Ratio
- VSTE N/A
- CMRX N/A
- Revenue Growth
- VSTE N/A
- CMRX N/A
- 52 Week Low
- VSTE $0.83
- CMRX $0.75
- 52 Week High
- VSTE $12.00
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- VSTE 55.09
- CMRX 60.78
- Support Level
- VSTE $0.83
- CMRX $0.80
- Resistance Level
- VSTE $1.09
- CMRX $0.98
- Average True Range (ATR)
- VSTE 0.10
- CMRX 0.05
- MACD
- VSTE 0.03
- CMRX 0.01
- Stochastic Oscillator
- VSTE 92.08
- CMRX 83.33
About VSTE Vast Renewables Limited
Vast Renewables Ltd is a clean, renewable energy company specializing in the design and manufacturing of concentrated solar thermal power (CSP) systems to generate carbon-free, utility-scale electricity, industrial heat, and green fuels. The Company's differentiated modular CSP system, utilizing proprietary sodium loop heat transfer technology, provides customers with a solution to the enduring challenge of intermittent renewable energy through 24/7 dispatchable power and heat.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.